Showing 7241-7250 of 7680 results for "".
- Novel Molecule Promising in Hyperhidrosis Pilot Studyhttps://practicaldermatology.com/news/20141016-novel_molecule_promising_in_hyperhidrosis_pilot_study/2459082/The outcome of a pilot study of BBI-4000, new compound for the topical treatment of primary axillary hyperhidrosis, support the potential for BBI-4000 to become a safe and effective treatment option for people suffering from excessive sweating. BBI-4000 is a new molecular entity from Brickell Biotec
- Syneron Launches PicoWay Picosecond Device for Pigmented Lesion Treatment and Tattoo Removalhttps://practicaldermatology.com/news/20141008-syneron_launches_picoway_picosecond_device_for_pigmented_lesion_treatment_and_tattoo_removal/2459094/Syneron Medical Ltd. launched its new PicoWay picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress, held in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a dual wavelength device, with 532nm and 1064nm wavelengths, which util
- Mission Pharmacal Unveils New Lotion for Seborrheic Dermatitishttps://practicaldermatology.com/news/20140930-mission_pharmacal_unveils_new_lotion_for_seborrheic_dermatitis/2459100/To help bring a treatment option to people afflicted with common skin disorders including seborrheic dermatitis (SD), Mission Pharmacal Company has unveiled Ovace Plus Lotion (sodium sulfacetamide 9.8%). Ovace Plus Lotion joins Ovace Plus Wash (sodium sulfacetamide 10%) Cleansing Gel and Ovace Plus
- GSK Presents Updated Results from Phase III BREAK-3 Study of Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140929-gsk_presents_updated_results_from_phase_iii_break-3_study_of_tafinlar_dabrafenib/2459102/Results from the planned analysis of the Phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma show benefit for the use of GSK's Tafinlar (dabrafenib) over dacarbazine (DTIC). Forty-five percent of patients treated with dabrafenib only were alive at two
- Foamix Pharmaceuticals Ltd. Closes Initial Public Offeringhttps://practicaldermatology.com/news/20140924-foamix_pharmaceuticals_ltd_closes_initial_public_offering/2459104/Foamix Pharmaceuticals Ltd. Closes Initial Public Offering A total of 6.7 million ordinary shares were sold at a price to the public of $6.00 per share. In addition, Foamix has granted the underwriters a 30 day option to purchase up to 1,005,000 additional ordinary shares. The sha
- Curcumin Nanoparticles Prevent Infections in Healing Woundshttps://practicaldermatology.com/news/20140922-curcumin_nanoparticles_prevent_infections_in_healing_wounds/2459114/Curcumin nanoparticles (curc-np) inhibit in vitro growth of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in dose-dependent fashion, and inhibits MRSA growth and enhances wound healing in an in vivo murine wound model, new research in the journal
- The ISDS Welcomes the Dermatology Community to Jerusalemhttps://practicaldermatology.com/news/20140917-the_international_society_for_dermatologic_surgery_welcomes_the_dermatology_community_to_jerusalem/2459116/The 35th Annual International Society for Dermatologic Surgery (ISDS) Congress will be held in Jerusalem from October 22-24, 2014. The ISDS will have the newest and latest techniques dermatologic surgery, skin cancer surgery, laser surgery, hair transplantation, varicose veins, lipolysis,
- Late Stage Skin Cancers on the Rise in the UK: World Congress on Cancers of the Skinhttps://practicaldermatology.com/news/20140917-late_stage_skin_cancers_on_the_rise_in_the_uk_world_congress_on_cancers_of_the_skin/2459119/Advanced-stage skin cancers are on the rise in the UK, according to two studies presented this month at the World Congress on Cancers of the Skin in Edinburgh, Scotland. The findings highlight an urgent need to publicise self-check and early detection messages, the The Skin Cancer Foundation says.
- Solace International Issues Recall of Dermatend Original and Dermatend Ultrahttps://practicaldermatology.com/news/20140902-solace_international_issues_recall_of_dermatend_original_and_dermatend_ultra/2459134/Solace International, Inc. is voluntarily recalling all lots of Dermatend Original and Dermatend Ultra in all sizes and dosage form to the distributor/wholesaler level. A mole should be removed under the supervision of a dermatologist. Dermatend is not FDA approved, thus has not
- MELA Sciences and Columbia University Imaging Experts Columbia Team Explore Potential Next Generation MelaFind Enhancementshttps://practicaldermatology.com/news/20140902-mela_sciences_and_columbia_university_imaging_experts_columbia_team_explore_potential_next_generation_melafind_enhancements/2459135/MELA Sciences, Inc.has executed a research agreement with Columbia University in which MELA and Columbia will collaborate to explore potential next generation capabilities and features of the MelaFind system and other enhancements to the system's range and ease of use. The company will have exclu